FGF21 and metabolic disease: In addition, the FGF21 analog LY2405319 (LY) with the half-life improving exerts an inhibitory effect on blood sugar and lipids, which indicates that the FGF21 pathway may be an ideal candidate for the treatment of metabolic diseases (Adams et al., 2013).